Acinetobacter baumannii (A. baumannii) is an important opportunistic pathogen widely present in medical environment. Given its complex drug resistance, A. baumannii poses a serious threat to the safety of critically ill patients. Given the limited alternative antibiotics, nonantibiotic‐based functional anti‐A. baumannii infection proteins must be developed. In this study, we firstly used a series of biological software to predict potential epitopes in the MacB protein sequence and verified them by antibody recognition and lymphocyte proliferation tests. We finally screened out B cell epitope 2, CD8+ T cell epitope 7, and CD4+ T cell epitope 11 and connected them to construct a recombinant antigen epitope (RAE). The determination of IgG in the serum of immunised mice and cytokines in the supernatant of lymphocytes showed that the constructed epitope induced an immune response mediated by Th‐1 cells. Finally, the challenge experiment of A. baumannii infection in mice confirmed that the epitope developed based on MacB, especially RAE, provided incomplete immune protection for mice.
Background: Spontaneous pneumomediastinum is a rare complication in COVID-19. Severe pneumonia complicated with pneumomediastinum after renal transplantation is rarely reported. Here we report a case of pneumomediastinum before invasive mechanical ventilation (IMV) in a COVID-19 patient with long-term immunosuppressive therapy after renal transplantation. Case presentation: A 57-year-old man was admitted to our center with the main complaint of “fever and dyspnea for 5 days”. His past medical history was notable for renal transplantation and with long-term immunosuppressive and anti-rejection therapy. We made the diagnosis as COVID-19 pneumonia (severe type). We managed the patient with high flow nasal cannulae (HFNC), oral dexamethasone, broad-spectrum antibiotic, prophylactic anticoagulation, and anti-viral therapy with reduced dose of azvudine due to severe renal insufficiency. During hospitalization, the patient suffered from several times of aggravation of dyspnea. First bedside chest X-ray showed suspicious pneumomediastinum and subcutaneous emphysema, and the gas in the mediastinum gradually increased. The patient’s status deteriorated rapidly, we performed urgent trachea intubation and mechanical ventilation with low tidal volume lung-protective model and performed mediastinal decompression by suprasternal drainage. Despite our active rescue efforts, the patient still died of severe infection and multiple organ failure. Conclusions: In conclusion, we are the first to report spontaneous pneumomediastinum in a renal transplant recipient with severe COVID-19 pneumonia. This case reminds us that pneumomediastinum is a severe complication and a poor prognostic factor of COVID-19 pneumonia, especially when it occurred without positive pressure ventilation and in immunocompromised patients.
Background Patients with gastroesophageal reflux cough were always given drugs treatment to relieve symptoms. But most of these patients were found to have unhealty diatery habits. To develop a new strategy to assist drugs therapy, the study was conducted. Objective To explore the clinical significance of “SLOW” strategy in the treatment of suspected gastroesophageal reflux cough. Methods A prospective study was conducted to select 122 patients diagnosed with chronic cough and suspected with gastroesophageal reflux cough who were admitted to Qilu hospital of Shandong University (Qingdao) from January 2015 to December 2017. Patients were randomly divided into experimental group (n=72) and control group (n=50). The experimental group was given omeprazole 20mg bid po + domperidone 10mg tid po + “SLOW” strategy, while the control group was only given omeprazole 20mg bid po + domperidone 10mg tid po. Hsu cough scoring system was used to analyze and evaluate the efficacy after 4 weeks of treatment. Results Among the 72 patients in the experimental group, 56 were effective (77.8 %), of which 44 cases were completely alleviated (61.1 %). Of the 50 control group patients, 27 were effective (54.0 %), of which 19 were in complete remission (38.0 %). The Hsu cough score showed a significant decrease in the scores of the experimental group, which was statistically significant compared with that of the control group (P<0.05). Conclusion The “SLOW” strategy, as a supplement to drug therapy, can increase the efficiency of treatment and significantly reduce the Hsu cough score.